Phase 4 Triamcinolone Dose Comparison for Knee Osteoarthritis: 40mg Landmark-Guided vs 20mg Ultrasound-Guided
ClinicalTrials.gov Studies
Summary
NCT07544576 is a Phase 4 randomized clinical trial registered on ClinicalTrials.gov comparing two Triamcinolone injection protocols for knee osteoarthritis: a 40mg landmark-guided dose versus a 20mg dose administered with ultrasound guidance. The study aims to determine whether the lower ultrasound-guided dose can achieve comparable efficacy while potentially reducing side effects. Eligible participants are adults with knee arthritis requiring corticosteroid injection therapy.
“The purpose of this study is to determine whether a lower dose of corticosteroid injection with ultrasound-guidance for the treatment of knee osteoarthritis can be as effective as a higher dose that is landmark-guided.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 588 changes logged to date.
What changed
This entry registers a new Phase 4 clinical trial (NCT07544576) on ClinicalTrials.gov. The study compares two Triamcinolone corticosteroid injection dosing strategies for knee osteoarthritis: a standard 40mg landmark-guided approach versus a 20mg dose with ultrasound guidance. The protocol examines whether reduced-dose ultrasound-guided injections can match the efficacy of higher landmark-guided doses while decreasing adverse effects.
Healthcare providers and clinical researchers treating knee osteoarthritis should note this comparative effectiveness study may inform future corticosteroid injection protocols. Patients meeting eligibility criteria may inquire about enrollment at participating trial sites.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Comparing Treatment of Knee Osteoarthritis With Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance
Phase 4 NCT07544576 Kind: PHASE4 Apr 22, 2026
Abstract
The purpose of this study is to determine whether a lower dose of corticosteroid injection with ultrasound-guidance for the treatment of knee osteoarthritis can be as effective as a higher dose that is landmark-guided. With landmark-guided dosing, it may be reasonable to use a higher amount of corticosteroid in order to ensure a sufficient amount of the medication is administered, however these injections carry the risk of side effects. Alternatively, with the use of ultrasound, it may be reasonable to use less corticosteroid, possibly decreasing the risk of side effects and increasing patient satisfaction.
Conditions: Knee Arthritis Osteoarthritis
Interventions: Triamcinolone knee injection without ultrasound guidance, Triamcinolone knee injection with ultrasound guidance
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM/NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.